Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SORD | Q00796 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952436 | 0.70 | TSHR (0.72) | TSHRL3MBTL1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8437512 | 0.68 | TSHR (1.00) | TSHRL3MBTL1RAB9ASMN1; SMN2ALDH1A1 | |
| Benzisothiazole-3Yl-Piperazine Sulfoxide SCHEMBL2967002 | 0.68 | TSHR (0.68) | TSHRL3MBTL1RAB9ASMN1; SMN2ALDH1A1 | |
| Saccharin SCHEMBL7361433 | 0.66 | ALDH1A1 (0.53) | TSHRALDH1A1POLBRXFP1 | |
| SCHEMBL27596185 | 0.63 | ALDH1A1 (0.68) | TSHRL3MBTL1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29695488 | 0.63 | ALDH1A1 (0.50) | TSHRL3MBTL1ALDH1A1POLB | |
| SCHEMBL299692 | 0.63 | ALDH1A1 (0.50) | TSHRL3MBTL1ALDH1A1POLB | |
| SCHEMBL10469851 | 0.62 | SMN1; SMN2 (0.67) | TSHRRAB9ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL30896637 | 0.62 | GAA (0.65) | TSHRL3MBTL1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7638951 | 0.60 | ALDH1A1 (0.51) | TSHRRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674810-B2 | 1,1-dioxo-1H-1Λ6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydro-pyrrol-2-one inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060252785-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252785-A1 | Heterocyclic antiviral compounds | EIF2AK2, HAVCR2, POLR2E | TSHR 3105/4885L3MBTL1 2580/4885RAB9A 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.